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Infection, https://doi.org/10.1016/j.jhin.20many of NICE’s suggestions represent an attempt to provide
pragmatic advice. For example, although ‘no suitable studieschoices must therefore balance adequate pathogen coverage
with the increased risk of Clostridium difficile, death andThe influential UK National Institute for Health and Care
Excellence (NICE) has recently published prescribing guidelines
for hospital-acquired pneumonia (HAP) [1]. The recognition is
welcome as HAP is responsible for more deaths and greater
morbidity than other healthcare-associated infections, with an
estimated in-hospital mortality rate between 18% and 29%
[2e4].
NICE bemoans the lack of evidence to support their rec-
ommendations, and these frustrations echo the sentiments of
recent American and European HAP guidelines [5,6]. No sys-
tematic reviews of HAP management are available and only
nine trials met the NICE criteria. The UK contributed a total of
10 patients to the evidence base [7]. Extrapolating evidence
from multi-centre clinical trials which recruited from multiple
countries with markedly varying HAP aetiological and anti-
microbial resistance profiles is fraught with difficulty.
Reflecting this, the guidelines recognize the importance of
local antibiograms, even to the level of individual wards, andof Infection and Global
7BE, UK.
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mons.org/licenses/by/4.0/).
., The challenge of antimicro
19.11.002examining the timing of antibiotic administration in HAP were
available’, NICE suggests that antibiotics should be adminis-
tered within 4 h of x-ray confirmation of HAP, which would
allow pre-antibiotic, diagnostic specimens to be obtained.
A central tenet of antibiotic prescribing is to understand
local epidemiology, and studies have demonstrated major
differences in the rates of pneumonia pathogens and resistance
at national and continental level [8]. Empirical antibiotic
antimicrobial resistance attributed to some antibiotic classes
[9]. In this context, NICE focuses on antibiotic stewardship, and
reinforces the importance of diagnostic microbiological sam-
ples such as sputum, nasopharyngeal swabs or tracheal
aspirates.
These guidelines triage patients into two groups based on
clinical severity and risk of resistant pathogens. Oral co-
amoxiclav is recommended for adults and children with low
clinical severity and low risk of resistant bacteria. The assess-
ment of severity is based on ‘clinical judgement’ as there are
‘no validated severity assessment tools’. Resistance risk
includes ‘ . recent use of broad-spectrum antibiotics’ and
‘recent contact with health and social care settings’. These
descriptions are ambiguous and it is likely that local inter-
pretation will result in the majority of patients being assigned
to the higher-risk algorithm where the suggested options are:
piperacillin-tazobactam, ceftazidime, ceftriaxone, cefurox-
ime, meropenem, ceftazidime-avibactam or levofloxacin. This
list is worthy of comment as NICE recognizes that high-risk HAP
is associated with Pseudomonas aeruginosa and organisms
carrying extended-spectrum beta-lactamases (ESBLs). How-
ever, the inclusion of agents such as ceftriaxone and cefurox-
ime, which lack activity against P. aeruginosa and organismshe Healthcare Infection Society. This is an open access article
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principle of ‘start smart, then focus’ [10]. The widespread
usage of these agents risks further propagating the spread of
ESBL- and AmpC-producing organisms, as well as exposing
patients to an elevated risk of C. difficile disease. NICE rec-
ommends that antibiotics for meticillin-resistant Staph-
ylococcus aureus (MRSA) should only be considered in the
presence of specific risk factors or when MRSA is confirmed.
This guidance reflects the comparatively low rates of MRSA
pneumonia in the UK compared with other countries, and is
aimed at avoiding unnecessary exposure to drug toxicity asso-
ciated with MRSA treatment [5,11].
However, the lack of evidence for some recommendations in
this guideline risks worsening the already confusing system of
pneumonia classification. NICE recommends that low-risk
patients who develop HAP between the third and fifth days of
their admission should be treated empirically as per guidance
for community-acquired pneumonia (CAP). This ambiguous
situation e HAP being treated as CAP e adds to the current
confusion stemming from the 2009 British Thoracic Society CAP
guidelines [12]. Those guidelines specifically excluded patients
who had a hospital admission within 10 days of developing
pneumonia, regarding those patients as having HAP. Therefore,
some CAP are treated as HAP and some HAP are treated as CAP.
In summary, HAP represents a huge challenge for antibiotic
stewardship, and the new NICE guidelines begin to address this
unmet need. However, the paucity of quality research avail-
able fails to address the root problem in pneumonia manage-
ment, namely the inadequacy of empirical prescribing. Rapid
diagnostic platforms are emerging that may enable personal-
ized antibiotic treatment. However, the clinical impact of
these new platforms is unproven and must be evaluated in
randomized controlled trials. Those trials will require novel
designs and outcome measures to tease out the morbidity,
mortality and costs that are attributable to HAP as opposed to
the condition precipitating hospitalization. NICE have pre-
viously suggested that a key outcome would be demonstrating
that new diagnostics can reduce antibiotic use whilst main-
taining effectiveness. If this could be demonstrated in such a
way as to be locally applicable, this would represent a huge
step forward.
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